Golcadomide not checked
Celgene · BMS-986369 · CC-99282
FollowEvery change as it happens, and a Monday email
Trials
12 active
18 in total · 9 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “CC-99282 by mouth at the assigned dose starting on Day 1 for 7 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.”In the company’s words, NCT04884035 on ClinicalTrials.gov
- Tested for
- Large B-cell Lymphoma, Follicular Lymphoma, Lymphoma, Follicular, Relapsed or Refractory T-cell Lymphomas, Lymphoma, Non-Hodgkin, Relapsed/Refractory Non-Hodgkin Lymphoma, Kidney Failure, Chronic, Lymphoma, B-Cell
- Main trialPhase 3
- “The purpose of this study is to compare the effectiveness and safety of golcadomide in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy vs placebo in combination with R-CHOP chemotherapy in participants with previously untreated high-risk large B-cell lymphoma (LBCL).”In the company’s words, NCT06356129 on ClinicalTrials.gov
- Other names
- BMS-986369 · CC-99282
Other drugs for Large B-cell Lymphoma
- IbrutinibJohnson & Johnson (Janssen) · Phase 3
- SelinexorKaryopharm Therapeutics Inc · Phase 2/3
- AcalabrutinibAstraZeneca · Phase 3
- EpcoritamabGenmab · Phase 3
- SHR-A1912Hengrui · Phase 3
- TisagenlecleucelNovartis · Phase 3
Coming up6
- 14 DecPhase 1 trial completes · ClinicalTrials.gov
- 7 Apr 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 9 Aug 2027Phase 3 trial completes · ClinicalTrials.gov
- 28 Oct 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 24 Apr 2028Phase 3 trial completes · ClinicalTrials.gov
- 1 Dec 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials18
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 9 Aug 2027 | Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma | |
| Phase 3Recruiting | 24 Apr 2028 | A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4) | |
| Phase 2Active, not recruiting | 19 Jun 2026 | A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma | |
| Phase 1/2Active, not recruiting | 11 Aug 2026 | A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3) | |
| Phase 1/2Active, not recruiting | 7 Apr 2027 | A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) | |
| Phase 1/2Recruiting | 28 Oct 2027 | A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas | |
| Phase 1Recruiting | 14 Dec 2026 | A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal Function | |
| Phase 1Active, not recruiting | 1 Dec 2028 | Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma | |
| Phase 1/2Completed | 15 Feb 2023 | A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies | |
| Phase 1Completed | 27 Dec 2022 | A Study to Evaluate the Metabolism and Excretion of BMS-986369 in Healthy Male Participants | |
| Phase 1Completed | 4 May 2023 | A Study to Evaluate the Drug Exposure of Single Ascending Doses of BMS-986369 and the Effect of Food on the BMS-986369 in Healthy Participants | |
| Phase 1Completed | 21 May 2024 | A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | |
| Phase 1Completed | 29 Aug 2024 | A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy Participants | |
| Phase 1Completed | 12 Nov 2025 | Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment | |
| Phase 2Authorised | not given | A combination of Rituximab and CC-99282 as front-line therapy for older frail patients with Diffuse Large B-cells non-Hodgkin Lymphoma evaluated with a simplified Geriatric Assessment (sGA): a phase II study of the Fondazione Italiana Linfomi (FIL). | |
| Phase 2Authorised | not given | CARMOD - Golcadomide (BMS-986369) post-CAR T-cell in R/R Aggressive large B-cell lymphoma patients with high risk of relapse | |
| Phase 1/2Authorised | not given | PLATFORM - A PLATFORM TRIAL, EVALUATING NEW DRUGS OR COMBINATION IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMAS | |
| Phase 2Authorised | not given | HOVON 176: Golcadomide (CC-99282) for relapsed and refractory primary large B-cell lymphoma of the central nervous system and secondary central nervous system lymphoma: a phase 2 study |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026